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The Association Between Low Socioeconomic
Status With High Physical Limitations and
Low Illness Self-Perception in Patients With
Juvenile Idiopathic Arthritis: Results From the
Childhood Arthritis Prospective Study
SUZANNE M. M. VERSTAPPEN,1 JOANNA COBB,1 HELEN E. FOSTER,2 BO FU,3 EILEEN BAILDAM,4
LUCY R. WEDDERBURN,5 JOYCE E. DAVIDSON,6 JOHN IOANNOU,7 ALICE CHIENG,8
KIMME L. HYRICH,1 AND WENDY THOMSON9
Objective. To examine the association between socioeconomic status (SES) and delay to a pediatric rheumatology clinic,
disease severity, and illness perception in patients with juvenile idiopathic arthritis in England.
Methods. Using the Index of Multiple Deprivation, 923 consecutive children from the Childhood Arthritis Prospective
Study were assigned to SES groups: high-SES (19.1%), middle-SES (44.5%), or low-SES (36.4%). At baseline, disease
activity was assessed, and the Childhood Health Assessment Questionnaire (C-HAQ), the Illness Perception Question-
naire, and the Child Health Questionnaire, version Parent Form 50, were completed. Linear median regression analyses
or zero-inflated negative binominal (ZINB) regression analyses were used.
Results. Delay to first pediatric rheumatology consultation was the same between the 3 SES groups. Although disease
activity scores assessed by the pediatric rheumatologist did not differ between the 3 SES groups, persons in the low-SES
group recorded higher C-HAQ scores compared to the high-SES group (zero-inflated part of ZINB odds ratio 0.28 [95%
confidence interval (95% CI) 0.14, 0.55], count part of ZINB  0.26 [95% CI 0.05, 0.48]). Parents with low SES also reported
more often that their children’s school work or activities with friends had been limited. Furthermore, the low-SES group
had a worse perception about the consequences of the disease and the effect of treatment than those in the high-SES group.
Conclusion. Patients from a low-SES background report more problems with daily activities and have a lower
perception of the consequences of the disease than patients from a high-SES background, warranting special attention
from a multidisciplinary team.
INTRODUCTION
Juvenile idiopathic arthritis (JIA) is a chronic inflamma-
tory disease of childhood with an incidence in the UK
estimated to be 10 per 100,000 (1). JIA is a heterogeneous
disease, and during childhood and adolescence many pa-
tients experience physical and psychosocial limitations,
including functional disability, pain, absence from school,
and difficulties participating in other activities such as
sports (2,3). JIA not only causes problems during child-
hood and adolescence, but joint damage accrued during
these years and ongoing exacerbations of inflammation are
associated with functional and socioeconomic conse-
quences into adulthood (2,4,5). With respect to the latter, a
few studies have shown that despite higher rates of school
absence, patients with JIA have similar or above average
high school grades compared to the general population in
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the UK, but patients with JIA are less likely to be employed
after leaving school (6–8).
Socioeconomic status (SES) may not only be a conse-
quence of poor health, but may also influence many as-
pects of health and well-being (9,10). Research has shown
inequity due to differences in SES regarding access to
health care systems and drugs, across countries and within
countries (11). SES is often measured at an individual
level based on formal education, income, social class, or
occupation. In addition to differences in individual back-
grounds, people are also affected by their environment and
the opportunities to live in certain areas (i.e., deprivation
at an area level). Although these concepts of measuring
SES differ slightly, they have both shown to exhibit inde-
pendent effects on outcome in arthritis and are used inter-
changeably, and thus are both referred to as SES in this
article (12). In populations including patients with adult
rheumatoid arthritis, those from deprived areas have more
severe disease activity early in the course of the disease
and have worse disease progression over time (13–15), but
conflicting results have been found with respect to access
to health care (16). Little is known in JIA about the impact
of SES on disease severity, illness perception, and delay to
pediatric rheumatology at presentation. In 1 US study of
295 patients with JIA, the patients on Medicaid, a health
care program for those with low income and resources,
had higher disability and lower health-related quality of
life compared with privately insured JIA patients, suggest-
ing an adverse impact of low SES (17). Both groups of
patients had similar access to care, with the exception of
magnetic resonance imaging (MRI), because privately in-
sured patients were almost twice as likely to receive MRI
scans, giving the chance of tighter disease control. Early
and tight disease control is essential, and delay in referral
may have a profound effect on long-term outcomes such as
joint damage and functional disability. Parents with higher
education are more likely to see a pediatric rheumatologist
early than parents with minimal or no education (18).
Controversial results have been found when looking at
the association between distance from a patient’s home to
the clinic as a proxy for SES in referral to a pediatric
rheumatologist (18,19). The results from these studies sug-
gest that factors associated with SES may play a role in
disease outcomes. Although no definitive measure exists,
by directly investigating SES via more accurate measures
such as area-specific deprivation scores, in addition to
more detailed data on outcomes, we could gain a clearer
understanding of the impact of SES on disease related
variables at presentation and delay to access in patients
with JIA.
The aims of the present study were to investigate the
impact of SES on disease severity early in the disease, on
delay in accessing pediatric rheumatology care, and on
illness perception in the Childhood Arthritis Prospective
Study (CAPS), a large observational cohort of patients with
JIA in the UK followed over time.
PATIENTS AND METHODS
Participants were children (ages 16 years) with inflam-
matory arthritis of at least 1 joint persisting for 2 weeks
who were recruited to the study. CAPS is a multicenter
study in the UK with an overall aim to identify genetic and
environmental predictors of short-term and long-term out-
comes of inflammatory arthritis. Details of this study have
been described elsewhere (4,20). CAPS was approved by
the North-West Multi-Centre Research Ethics Committee.
Written informed consent was obtained from the parent(s)/
guardian for all participating children according to the
Declaration of Helsinki, and children considered able were
asked to provide age-appropriate assent.
Baseline data collection. At baseline (the first visit to a
pediatric rheumatologist), the rheumatologist examined
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Significance & Innovations
● Parents of patients with juvenile idiopathic arthri-
tis (JIA) or children with JIA from a lower socio-
economic background report more functional dis-
ability, while disease activity according to the
pediatric rheumatologist is the same.
● Parents of patients with JIA from a lower socioeco-
nomic background more often report that their
children’s school work or activities with friends
had been limited due to emotional difficulties or
problems with their behavior.
● In this cross-sectional study, parents of patients
with JIA or children with JIA have different per-
ceptions regarding the burden of the disease, de-
pending on socioeconomic background, warrant-
ing special attention from a multidisciplinary team
over a longer period of time to understand the
causal relationship of this finding.
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the joints, recording the number of limited and active
joints (out of 71 joints), completed a 100-mm physician’s
global visual analog scale (VAS; range 0–100 mm, where
100 is the worst score) and assigned an International
League Against Rheumatism (ILAR) subtype of JIA based
on the disease characteristics at the time of presentation
(21). In addition, the parents and child were interviewed
by a rheumatology research nurse, and the medical records
were reviewed to extract data on demographics (age, sex,
diagnosis, source of referral, disease duration, past medi-
cal history, medication use, and relevant blood tests, such
as erythrocyte sedimentation rate [ESR]). The parent or
child, where appropriate, completed the British version
of the validated Childhood Health Assessment Question-
naire (C-HAQ), a measure of functional disability (range
0–3, where 3 is the worst) (22), a 100-mm VAS pain scale,
and a 100-mm parent/patient global measure. The C-HAQ
was completed by the parent if the child was 10
years or by the child if age 11 years. The active joint
count, physician’s global assessment, ESR, and parent/
patient global assessment were used to calculate the Juve-
nile Arthritis Disease Activity Score based on 71 joint
count (JADAS-71) and the JADAS3-71 (which excludes
ESR) (23), as a measure of disease activity.
To evaluate the perception of how a child’s arthritis
affects their life, the Illness Perception Questionnaire
(IPQ) (24) was also completed by the parent (child age10
years) or by the child (age11 years). In this study we only
included section 2 of the IPQ, evaluating the personal
views about JIA. Answers were rated on a 5-point Likert
scale, ranging from “strongly disagree” to “strongly agree.”
The Child Health Questionnaire (CHQ), in the version
Parent Form 50 (CHQ-PF50) (25) was completed by the
parents of children ages 5 years (see Supplementary
Appendix A, available in the online version of this article
at http://onlinelibrary.wiley.com/doi/10.1002/acr.22466/
abstract, for a description of the IPQ and CHQ-PF50 items
included in the current study). To aid interpretation of the
CHQ-PF50 scores, scores were reversed in the current
study (i.e., higher scoreworse score). Both the IPQ (from
September 2003) and the CHQ (from December 2001) were
introduced a few years after the start of CAPS, and there-
fore fewer parents/children completed these forms.
SES. For the present study, we used postal codes to
assign each patient to a nationwide deprivation rank by
using the most recent nationwide Index of Multiple Depri-
vation (IMD) score compiled in 2007 (http://geoconvert.
mimas.ac.uk/). We then assigned patients to nationally
determined quartiles of deprivation (the lowest quartile 
least deprived group [high-SES], the middle 2 quartiles 
middle-SES group, and the highest quartile  most de-
prived SES group [low-SES]). The IMD is a measure of
multiple deprivations at the small-area level. It breaks the
areas down to the lower super output area level (a mini-
mum population area of 1,000 people). These levels are
a constant size across England and not subject to the
regular boundary changes of electoral wards, and they
combine indicators from economic, social, and housing
issues into a single deprivation score. Seven separate
weighted domain scores were combined to make the
IMD, including income, employment, health depriva-
tion, disability, education, skills, training, barriers to
housing and services, crime, and living environment.
Only children recruited in England were included in the
present study, since the IMD is only based on data
collected in England.
Statistical analysis. Descriptive data, including demo-
graphics, disease characteristics (JADAS3-71, JADAS-71,
active and limited joints, physician global, parent global,
and C-HAQ scores), IPQ item scores, and CHQ-PF50 item
scores, were presented for the total study population
and divided by SES group (low-SES, middle-SES, and
high-SES groups). Logistic regression analyses were used
for binary outcomes. For continuous variables, the associ-
ation between SES and baseline characteristics was inves-
tigated by applying univariate linear regression analysis,
median regression analysis, or zero-inflated negative bi-
nominal (ZINB) regression analysis, depending on the dis-
tribution of the data. Median regression is a robust alter-
native to the usual linear (mean) regression when the
linear regression assumptions, mainly the assumption of
normality of the residuals, is violated due to skewed dis-
tributions for response variables (26). ZINB regression ana-
lysis allows for an excessive number of outcome zeros by
assuming that zero outcome is due to 2 different processes.
First, a logit model is generated to predict whether a
child belongs to the certain-zero group. Second, a negative-
binominal model is generated to predict the counts for
those children who are not certain zeros (27). The Vuong
statistic was considered for the zero-inflated model to de-
termine whether it is an improvement over the standard
negative-binomial model. Beta coefficients were trans-
formed into odds ratios (ORs) for the zero-inflated part.
The C-HAQ score was one of the outcomes for which ZINB
regression analysis was applied, and the C-HAQ score
(0.125 incremental scale) was therefore multiplied by 8
to obtain counts. A multinominal logistic regression ana-
lysis was applied to assess the association between SES
and point of referral. All analyses were undertaken using
STATA software, version 11.0.
RESULTS
A total of 923 children with a median age at symptom
onset of 6.7 years (95% confidence interval [95% CI] 2.8,
10.7) for whom the IMD rank could be determined were
included in the study (Table 1). The majority of patients
(89%) were from a white cultural background, 4% were
from a mixed background, and 7% were from Asian, black,
or other background. The median C-HAQ score was 0.625
(95% CI 0.125, 1.375), and the recorded CHQ-PF50 scores
of all items were higher than previously seen in healthy
children (25). The mean  SE original score for physical
function was 61  1.8 versus 96  0.8, and for role/social
limitations–emotional/behaviorial 73.5  1.8 versus
92.9  0.9, healthy children versus JIA patients, respec-
tively.
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Patients with available C-HAQ scores, IPQ score, or
CHQ-PF50 scores did not differ from patients without
these scores with respect to age, sex, or limited and ac-
tive joint count. However, median physician global score
was significantly higher in those with available data
compared to those with missing data: C-HAQ 30 (95% CI
17, 57) versus 24 (95% CI 13, 45), P  0.0016; IPQ 32
(95% CI 16, 58) versus 24 (95% CI 11, 47), P  0.0028;
CHQ-PF50 31 (95% CI 17, 59) versus 23 (95% CI 10, 42),
P  0.001.
SES and disease subtypes. Based on the national IMD
ranking distribution, 176 children (19.1%) were assigned
to the high-SES group, 411 (44.5%) to the middle-SES
group, and 336 (36.4%) to the low-SES group. At baseline,
the percentages of patients according to the ILAR JIA
subtypes for the high-SES, middle-SES, and low-SES
groups were systemic arthritis (8.0%, 6.4%, and 3.6%,
respectively), persistent oligoarthritis (47.5%, 50.7%, and
53.4%, respectively), extended oligoarthritis (2.5%, 2.4%,
and 1.6%, respectively), rheumatoid factor–negative poly-
arthritis (19.1%, 18.8%, and 14.3%, respectively), rheu-
matoid factor–positive polyarthritis (2.5%, 3.0%, and
4.6%, respectively), enthesitis-related arthritis (5.6%,
5.9%, and 4.2%, respectively), psoriatic arthritis (6.2%,
4.0%, and 6.2%, respectively), and unclassifiable/other
(8.6%, 8.8%, and 12.1%, respectively).
Table 1. Baseline demographic and disease characteristics*
N Value
Age at onset, years 923 6.7 [2.8–10.7]
Female, n (%) 923 581 (63)
Delay to rheumatologist, months 920 5.6 [2.9–12.0]
Active joint count 905 2 [1–4]
Limited joint count 905 1 [0–3]
Physician global assessment, mm 713 29 [15–51]
ILAR subtype, n (%) 842
Systemic arthritis 48 (5.7)
Persistent oligoarthritis 430 (51.1)
Extended oligoarthritis 18 (2.1)
RF-negative polyarthritis 145 (17.2)
RF-positive polyarthritis 29 (3.4)
Enthesitis-related arthritis 44 (5.2)
Psoriatic arthritis 44 (5.2)
Unclassifiable 50 (5.9)
Other inflammatory arthritis 34 (4.0)
JADAS-71 304 11.2 [5.8–17.2]
JADAS3-71 477 8.8 [4.5–14.0]
C-HAQ score 601 0.625 [0.125–1.375]
VAS pain, mm 589 30 [8–58]
VAS general evaluation, mm 582 21 [4–50]
IPQ, mean  SD
Timeline (range 5–30) 225 17.1  4.2
Consequences (range 0–30) 225 18.4  5.0
Personal control (range 5–25) 225 18.7  4.4
Treatment control (range 5–25) 225 18.6  2.9
Illness coherence (range 5–25) 225 15.7  4.5
Timeline cyclical (range 5–20) 225 12.7  2.9
Emotional representations (range 5–30) 225 18.7  5.4
CHQ
Physical functioning 353 33 [6–67]
Role/social limitations–emotional/behavioral 351 0 [0–56]
Role/social limitations–physical 352 33 [0–67]
Bodily pain/discomfort 334 60 [30–80]
Behavior 334 28 [15–44]
Mental health 333 25 [15–40]
Self-esteem 334 29 [13–46]
Parental impact, emotional 354 33 [17–67]
Parental impact, time 352 11 [0–33]
Family activities 354 25 [8–46]
Family cohesion 354 15 [15–40]
* Values are the median [interquartile range], unless otherwise indicated. ILAR  International League
Against Rheumatism; RF  rheumatoid factor; JADAS-71  Juvenile Arthritis Disease Activity Score
based on 71 joint count; JADAS3-71  JADAS-71 without erythrocyte sedimentation rate; C-HAQ 
Childhood Health Assessment Questionnaire; VAS  visual analog scale; IPQ  Illness Perception
Questionnaire; CHQ  Child Health Questionnaire.
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Association between socioeconomic status and clinical
and patient-reported outcomes. The relationships be-
tween socioeconomic status and clinical and patient-
reported outcomes at baseline are shown in Table 2. Age
at onset and sex did not differ significantly between
the SES groups. Although delay to first rheumatology visit
did not differ significantly between the 3 SES groups,
more patients in the low-SES group were referred via the
emergency room, general practitioner, or orthopedicsthan by
pediatrics compared to patients in the high-SES group.
Table 2. Relationships between socioeconomic status (SES) and clinical and patient-reported outcomes*
High-SES group,
reference group
(n  176)
Middle-SES
group
(n  411)
Middle- vs.
high-SES
group
Low-SES
group
(n  336)
Low- vs.
high-SES
group
Age at onset, years 6.3 [2.8–10.2] 6.0 [2.5–10.5] 0.31 (1.59, 0.97)† 7.4 [3.3–11.2] 1.07 (0.26, 2.39)†
Sex, female 109 (62) 261 (64) 0.93 (0.65, 1.35)‡ 211 (63) 0.96 (0.66, 1.40)‡
Source of referral
Emergency room 3 (1.7) 17 (4.3) 1.01 (0.25, 2.26)§ 28 (5.6) 1.96 (0.74, 3.19) sig.§
General practitioner 30 (17.1) 62 (15.5) 0.001 (0.51, 0.50)§ 66 (20.2) 0.52 (0.004, 1.03) sig.§
Orthopedics 38 (21.7) 113 (28.3) 0.36 (0.09, 0.81)§ 105 (32.1) 0.75 (0.28, 1.21) sig.§
Pediatrician 87 (49.7) 180 (45) Comparator 114 (34.9) Comparator
Other 17 (9.7) 28 (7) 0.23 (0.88, 0.43)§ 14 (4.3) 0.46 (1.22, 0.30)§
Delay to pediatric
rheumatologist, months
5.3 [2.9–12.6] 5.9 [3.1–12.0] 0.56 (0.42, 1.55)† 5.6 [2.6–11.1] 0.27 (0.75, 1.28)†
Active joint count 2 [1–4] 1 [1–5] 0 (2.53, 2.53)† 2 [1–4] 0 (2.61, 2.61)†
Limited joint count 1 [0–3] 1 [1–3] 0 (2.31, 2.31)† 1 [0–3] 0 (2.38, 2.38)†
Physician global
assessment, mm
29 [13–53] 29 [15–51] 0 (7.11, 7.11)† 29 [17–51] 0 (7.32, 7.32)†
JADAS-71 10.2 [5.8–15.8] 10.8 [6–18.1] 0.60 (2.40, 3.60)† 12.2 [5.5–16.7] 2.2 (0.93, 5.33)†
JADAS3-71 10.2 [5.8–15.8] 10.8 [6–18.1] 0.30 (2.39, 1.79)† 12.2 [5.5–16.7] 0.80 (1.39, 2.99)†
C-HAQ score 0.5 [0–0.875] 0.625 [0.125–1.375] 0.37 (0.20, 0.67) sig.¶
0.10 (0.11, 0.30)#
0.875 [0.313–1.625] 0.28 (0.14, 0.55) sig.¶
0.26 (0.05, 0.48) sig.#
VAS pain, mm 18.5 [4–48] 30 [6–56] 1.08 (0.51, 2.28)¶
0.20 (0.01, 0.41)#
39 [13–63.5] 0.43 (1.16, 1.13)¶
0.29 (0.07, 0.51) sig.#
VAS general evaluation,
mm
15 [4–35] 20 [3–50] 1.54 (0.56, 4.20)¶
0.30 (0.06, 0.54) sig.#
30 [6–52] 0.46 (0.11, 1.86)¶
0.39 (0.14, 0.63) sig.#
IPQ
Timeline 15.7 (3.6) 17.5 (3.4) 1.73 (0.31, 3.14) sig. 17.5 (5.1) 1.75 (0.28, 3.22) sig.
Consequences 16.9 (4.8) 18.6 (4.8) 1.68 (0.00, 3.37) 19.2 (5.1) 2.32 (0.58, 4.07) sig.
Personal control 18.6 (4.0) 18.5 (3.7) 0.13 (1.63, 1.38) 18.9 (5.2) 0.22 (1.34, 1.78)
Treatment control items 19.9 (1.9) 18.1 (2.9) 1.76 (2.74, 0.77) sig. 18.5 (3.3) 1.38 (2.40, 0.36) sig.
Illness coherence items 17.0 (3.4) 15.7 (4.5) 1.24 (2.76, 0.28) 15.0 (4.8) 2.0 (3.59, 0.45) sig.
Timeline cyclical 12.4 (2.6) 12.6 (2.9) 0.19 (0.81, 1.20) 12.9 (3.1) 0.50 (0.54, 1.54)
Emotional representations 17.9 (4.2) 19.0 (5.8) 1.06 (0.79, 2.91) 18.7 (5.5) 0.77 (1.15, 2.69)
CHQ
Physical functioning 11.1 [0–44] 33 [11–67] 0.43 (0.23, 0.81) sig.¶
0.20 (0.01, 0.43)#
44 [11–72] 0.38 (0.19, 0.75) sig.¶
0.36 (0.11, 0.60) sig.#
Role/social limitations–
emotional/behavioral
0 [0–22] 0 [0–56] 0.87 (0.50, 1.52)¶
0.31 (0.06, 0.56) sig.#
22 [0–67] 0.66 (0.37, 1.18)
0.42 (0.16, 0.69) sig.#
Role/social limitations–
physical
17 [0–33] 33 [0–67] 16.67 (26.63, 59.96)† 50 [0–67] 33.33 (12.36, 79.03)†
Bodily pain/discomfort 50 [20–70] 60 [40–80] 10 (16.30, 36.30)† 60 [40–80] 10 (16.63, 36.63)†
Behavior 23 [14–32] 32 [19–44] 8.33 (2.79, 13.89) sig.† 25 [15–44] 1.67 (4.15, 7.48)†
Mental health 23 [15–35] 25 [15–40] 0 (13.0, 13.0)† 25 [15–45] 0 (13.4, 13.4)†
Self-esteem 25 [15–33] 29 [17–50] 0.49 (0.15, 1.61)¶
0.15 (0.04, 0.34)#
25 [13–45] 1.92 (0.72, 5.17)¶
0.14 (0.06, 0.34)#
Parental impact,
emotional
33 [17–50] 42 [17–67] 8.33 (14.09, 30.75)† 33 [17–67] 3.27e14 (23.29, 23.29)
Parental impact, time 11 [0–33] 11 [0–44] 0.996 (0.57, 1.74)¶
0.34 (0.08, 0.59) sig.#
11 [0–44] 0.71 (0.40, 1.29)¶
0.24 (0.02, 0.49)#
Family activities 17 [4–38] 25 [8–50] 0.79 (0.39, 1.59)¶
0.24 (0.01, 0.47) sig.#
29 [8–50] 0.58 (0.27, 1.25)¶
0.24 (0.01, 0.48) sig.#
Family cohesion 15 [15–40] 15 [15–40] 0 (40.64, 40.64)† 15 [15–40] 0 (42.65, 42.65)†
* Values for high-, middle-, and low-SES groups are median [interquartile range] for continuous variables and number (percentage) for categorical
variables. Comparison columns include values for -coefficent/odds ratio/rate ratio (95% confidence interval). Unless otherwise indicated by a
footnote, values are from -coefficient linear regression analysis. Sig.  statistically significant at P  0.05; JADAS-71  Juvenile Arthritis Disease
Activity Score based on 71 joint count; JADAS3-71  JADAS-71 without erythrocyte sedimentation rate; C-HAQ  Childhood Health Assessment
Questionnaire; VAS  visual analog scale; IPQ  Illness Perception Questionnaire; CHQ  Child Health Questionnaire.
† -coefficient median regression model.
‡ Odds ratio logistic regression model.
§ Rate ratio multinominal logistic model.
¶ Odds ratio zero-inflated part of ZINB model.
# -coefficient count part of ZINB model.
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No significant differences in median physician-reported
outcome scores were observed, including active joint
count, limited joint count, and physician global assess-
ment. In addition, both JADAS-71 and JADAS3-71 did not
differ significantly between the SES groups. Compared to
children in the high-SES group, those in the low-SES
group were significantly less likely to have a C-HAQ score
of zero (OR 0.28, [95% CI 0.14, 0.55], P  0.001), and
within the negative binominal part, the rate ratios indicate
that the mean C-HAQ score is approximately 30% higher
than in the high-SES group ( 0.26, [95% CI 0.05, 0.48],
P  0.015). Compared to the children in the high-SES
group, children in the middle-SES group were also less
likely to have a C-HAQ score of zero (OR 0.37, [95% CI
0.20, 0.67], P  0.01), but the results in the negative bi-
nominal part were not statistically significant. A similar
result was found for the physical activity score included in
the CHQ-PF50 questionnaire (Table 2). Although com-
pared to children in the high-SES group, children in the
low-SES group were not more likely to have excessive zero
scores for VAS pain and VAS general evaluation, but those
not scoring zero indicated they had more pain ( 0.07,
[95% CI 0.07, 0.51], P  0.010) and had a higher general
evaluation score ( 0.39, [95% CI 0.14, 0.63], P  0.002).
Compared to the high-SES group, parents or adolescents
in the middle-SES and low-SES groups thought that arthri-
tis had large consequences for themselves and their fam-
ily ( 1.68, [95% CI 0.00, 3.37], P  0.05 for middle-SES
versus high-SES, and  2.32, [95% CI 0.58, 4.07], P 0.009
for low-SES versus high-SES), and they thought that the
arthritis would last a long time ( 1.73, [95% CI 0.31, 3.14],
P  0.017 for middle-SES versus high-SES, and  1.75,
[95% CI 0.28, 3.22], P  0.020 for low-SES versus high-
SES) (Table 2). Furthermore, patients in the low-SES and
middle-SES groups thought that the arthritis treatment
would be less effective in curing the arthritis compared to
patients in the high-SES group ( 1.76, [95% CI 2.74,
0.77], P  0.001 for middle-SES versus high-SES, and 
1.38, [95% CI 2.40, 0.36], P  0.009 for low-SES
versus high-SES).
Compared to the high-SES group, parents of children
included in the middle-SES and the low-SES group scores
more often reported that their children’s school work or
activities with friends had been limited due to emotional
difficulties or problems with their behavior (role/social
limitations–emotional/behavioral:  0.31, [95% CI 0.06,
0.56], P  0.014 for the middle-SES group, and  0.42,
[95% CI 0.16, 0.69], P  0.001 for the low-SES group). The
same parents also more often reported that their child’s
health or behavior had an impact on the family’s activities
( 0.24, [95% CI 0.01, 0.47], P  0.039 for the middle-SES
group, and  0.24, [95% CI 0.01, 0.48], P  0.040 for the
low-SES group). When applying Bonferroni’s adjustment,
resulting in a P value of 0.0017, the findings for the C-HAQ
score remained statistically significant.
DISCUSSION
This is the first study looking at the association between
SES using national deprivation indices and disease sever-
ity at presentation, delay to pediatric rheumatology care,
and illness perception in patients with JIA. Despite similar
disease activity scores obtained in the clinic, patients
from a low-SES background rated their general disease
activity, pain, and functional disability worse than pa-
tients from a high-SES background. Parents from a low-
SES background also reported that their child with JIA had
been limited in their schoolwork or activities with friends
due to emotional difficulties, had problems with their
behavior and limited family activities, or had caused ten-
sion in the family. Part of these findings is similar to those
found in previous studies defining SES at an individual
level, such as insurance information (17), education level
of parents (18,19,28), living in a Canadian reserve (29), and
distance to health care centers (19). In this study we used
area deprivation level data, which conceptually might be
slightly different. SES levels measured at an individual
level and at an area level have both shown to be indepen-
dent predictors of arthritis health (12). A disadvantage of
using individual-level data in this study might have been
that the data will reflect the parent’s SES. Furthermore,
data on income and education of parents was missing
for a large proportion of our study population. We there-
fore chose to use SES based on area-level data because we
think they are probably more accurate, including data on
income, employment, health deprivation, disability, edu-
cation, skills, training, barriers to housing and services,
crime, and living environment. A disadvantage might be
ecological fallacy. The discrepancy between the observed
clinical findings and parent/patient-reported findings in
our study may partly be explained by unmeasured con-
founding such as comorbidities. Population-based surveys
have shown that children from deprived areas are more
likely to have other chronic diseases such as asthma and
diabetes mellitus (30–32).
We also found that the expectations in parents of chil-
dren and young adolescents with arthritis regarding the
duration of the disease, consequences of the disease, and
the effect of treatment were lower in patients with a low
SES compared to those with a high SES. This finding,
together with the findings that JIA has a greater impact on
a child’s schoolwork, activities with friends, and family in
families from a low SES, is of importance when discussing
the consequences of JIA with the child and their family in
the clinic. Advice to the family about how to cope with
the disease may therefore differ depending on the SES of
the child. A previous study also showed that children with
JIA from a low SES are less likely to adhere to their med-
ication (33). The results from our study and the earlier
study, therefore, warrant special attention from the pedi-
atric rheumatology multidisciplinary team to provide ad-
ditional social, psychological, and educational resources
and support to those children and families who we would
suggest are at greater risk of poor functional outcome. To
aid better support, we need to understand which factors
contribute to more disability and disease concerns in peo-
ple with a low SES. Is there a general difference in disease
perception between people with low and high SES, or are
higher disability scores partly explained by other factors
such as chronic comorbidities, as previously mentioned?
Providing better background information about the disease
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and its consequences could help adolescents or adults of
children with JIA to better understand the disease. To
determine which other factors may contribute to differ-
ences in patient-reported outcome scores, further research
is necessary into the sensitivity of these measures and the
discriminative ability in low- and high-SES groups over
time.
Unfortunately, one of the limitations of our study was
the cross-sectional design, and causation could not be
ascertained. However, we did find that patients in the
high-SES group were mainly referred to the pediatric rheu-
matologist via their pediatricians, whereas patients in the
low-SES group were more often referred via the emergency
room, or from other specialities. Interestingly, the delay
to the first pediatric rheumatologist appointment did not
differ between the 3 SES groups. Because the vast majority
of health care provision in the UK is public and free at
point of access, time to presentation should therefore not
be affected by affordability, but could affect delay in pre-
sentation, since first symptoms are based on personal cir-
cumstances and/or decisions. In a German study, delayed
referral was associated with the primary physician’s sub-
specialty (i.e., orthopedic surgeon) and distance to the
pediatric hospital, so that patients living in more remote
areas had the longest referral time (19). Notably, more
remote areas do not necessarily mean low SES, and it is
therefore difficult to compare the results, since we did not
calculate the distance between the child’s home address
and the hospital. To further entangle the relationship be-
tween SES and disease activity in JIA, longitudinal data
are required, since not only may SES impact disease-
related factors and patient-reported outcomes, but caring
for children with a chronic disease such as JIA may also
impact families’ cost of living and thus have an effect on
SES, in that families may have to pay for travel to hospi-
tals, pay for adaptations and devices, take days off from
work, or even stop working to take care of their child.
We were only able to include patients recruited to CAPS
from England and not those patients recruited from Scot-
land, because of the differences in defining deprivation
scores in England and Scotland. The postcode of the home
address where patients lived at the time of inclusion in
CAPS was used to determine the deprivation status. Pos-
sibly patients had not been living very long at that address.
However, even if they moved homes in the year prior to
inclusion, the SES is unlikely to have changed very much.
We sought to determine the association between SES and
quite a large number of demographic, clinical, and patient-
reported outcomes (n  30). Some findings may have been
significant by chance, although some variables remained
significant after adjusting for multiple tests.
In conclusion, the way parents and children perceive
the child’s illness and the consequences of the disease
differs between SES groups. Patients from a low-SES back-
ground score their disease activity and functional disabil-
ity higher than patients from a high-SES background,
whereas no differences were found in disease activity
scores obtained in the clinic. This study suggests that it is
important to take SES into account when patients with JIA
arrive at the clinic for the first time.
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